The FDA narrowed the indications for pembrolizumab (Keytruda) and nivolumab (Opdivo) in gastric, gastroesophageal junction ...

When it comes to the use of PD-1 inhibitors in stomach cancer, the FDA has put its money where its mouth is. | After ...

China NMPA accepts Hutchmed & Innovent’s NDA for fruquintinib in combo with sintilimab to treat advanced renal cell carcinoma: Hong Kong, Shanghai Friday, June 6, 2025, 09:00 Hr ...

Among individuals with achalasia, male sex, older age and prior esophageal Candida infection increased risk for esophageal ...

Esophageal cancer remains one of the world's deadliest cancers, ranking 7th in incidence and 6th in cancer-related deaths ...

Shlomo Koyfman, MD, discusses the MK-3475-630/ KEYNOTE-630 trial, which focused on patients with high-risk cutaneous squamous cell cancer. Shlomo Koyfman, MD, a radiation oncologist at Cleveland ...

Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier ...

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC ...

Endoscopy, which directly looks into diseases in our body, is undergoing a new evolution with the advent of artificial ...

Bcl6 regulates the lineage stability and suppressive function of Treg cells in head and neck squamous cell carcinoma Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer ...

Background: Esophageal squamous cell carcinoma (ESCC) represents a highly aggressive malignancy with poor prognosis and limited therapeutic advancements. While chimeric antigen receptor (CAR)-T-cell ...